Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer
Knowledge of the impact of gene expression profiling could allow optimisation of chemotherapy regimens for individual patients. It could ensure that patients do not receive a particular form of chemotherapy if it is unlikely to benefit them, and in these circumstances an alternative form of chemotherapy that may prove beneficial could be selected. This information will therefore allow chemotherapy to be tailored to the individual tumour. It may help identify those patients with a poorer prognosis who could be selected for further therapy post surgery or a different treatment strategy at the outset.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer|
- To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.
- Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.
|Study Start Date:||June 2002|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00220077
|Contact: Sheela Rao||0208 642 email@example.com|
|Contact: Naureen Starling||0208 642 firstname.lastname@example.org|
|Royal Marsden Hospital||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Contact: Sheela Rao 0208 642 6011 email@example.com|
|Contact: Naureen Starling 0208 642 6011 firstname.lastname@example.org|
|Principal Investigator: David Cunningham|
|Principal Investigator:||David Cunningham||Royal Marsden NHS Foundation Trust|